drugset
drugset / Trial / NCT03725072

Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib

NCT03725072 ↗

Phase 1 Completed 6 enrolled Merck KGaA, Darmstadt, Germany
NaSingle-groupOpen-labelOther

Summary

The purpose of the study is to determine the absorption, metabolism, and excretion of \[14C\]-evobrutinib in healthy participants

Timeline

Start
2018-10-30
Primary completion
2018-12-05
Completion
2018-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Evobrutinib Small molecule — Oral

Indications

No indication recorded.